Loading
A phase 1/2 trial of GSK5460025 in colorectal cancer, run by GlaxoSmithKline, now recruiting.
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07213609 by GlaxoSmithKline, with 47 participants planned, started 2025-10-20 and due to reach its primary completion in 2028-09-28. Interventions recorded: GSK5460025.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK, Colorectal cancer and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.